PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma

Reeder M. Robinson1 · Ashton P. Basar1 · Leticia Reyes1 · Ravyn M. Duncan1 · Hong Li2,3 · Nathan G. Dolloff1,3

Received: 20 December 2021 / Accepted: 10 March 2022 / Published online: 5 April 2022
© The Author(s) 2022

Abstract
The histone deacetylase inhibitor (HDACi), panobinostat (Pano), is approved by the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) for treatment of relapsed/refractory multiple myeloma (MM). Despite regulatory approvals, Pano is used on a limited basis in MM due largely to an unfavorable toxicity profile. The MM treatment landscape continues to evolve, and for Pano to maintain a place in that paradigm it will be necessary to identify treatment regimens that optimize its effectiveness, particularly those that permit dose reductions to eliminate unwanted toxicity. Here, we propose such a regimen by combining Pano with LTI6426, a first-in-class orally bioavailable protein disulfide isomerase (PDI) inhibitor. We show that LTI6426 dramatically enhances the anti-MM activity of Pano in vitro and in vivo using a proteasome inhibitor resistant mouse model of MM and a low dose of Pano that exhibited no signs of toxicity. We go on to characterize a transcriptional program that is induced by the LTI6426/Pano combination, demonstrating a convergence of the two drugs on endoplasmic reticulum (ER) stress pathway effectors ATF3 (Activating Transcription Factor 3), DDIT3/CHOP (DNA Damage Inducible Transcript 3, a.k.a. C/EBP Homologous Protein), and DNAJB1 (DnaJ homolog subfamily B member 1, a.k.a. HSP40). We conclude that LTI6426 may safely enhance low-dose Pano regimens and that ATF3, DDIT3/CHOP, and DNAJB1 are candidate pharmacodynamic biomarkers of response to this novel treatment regimen.

Keywords Multiple myeloma · Panobinostat · Protein disulfide isomerase · Epigenetic therapy · Histone deacetylase

Introduction
Global histone methylation and acetylation patterns are abnormal in MM and cancer as a whole [1–4]. Epigenetic dysfunction has therefore been implicated in MM disease etiology and epigenetic regulators such as HDACs have been proposed as therapeutic targets. Panobinostat (Pano), is a pan-HDACi that was approved by the FDA and EMA for treatment of relapsed/refractory MM in combination with the proteasome inhibitor bortezomib (Btz) and dexamethasone [5–7]. Pano potently inhibits nearly all classes of HDAC enzymes with IC50 values in the low nanomolar range and dramatically alters histone acetylation and gene transcription patterns in cells [8]. Despite the strengths of Pano as a drug candidate, its clinical impact has been limited compared to other novel MM agents. This is due in part to grade 3/4 toxicities including hematological adverse events (AEs), diarrhea, and fatigue [7, 9, 10], although these AEs apparently result from the combination with Btz, as they are far less frequent and severe with Pano monotherapy [10–12]. It is possible that Pano combinations with other standard of care MM agents could offer benefits to patients with improved tolerability. For example, recent studies using a steroid-sparing regimen combining Pano with the second generation proteasome inhibitor, carfilzomib [13, 14], demonstrated efficacy with limited toxicity and dosing flexibility. Therefore, it is possible that the optimal clinical context for Pano in the complex MM treatment paradigm is still evolving [15]. Additional work in this area could reveal a more optimal clinical setting for Pano, and it is our position that...
further studies are warranted considering the large body of work implicating epigenetic dysregulation in MM.

In this study we propose a new therapeutic strategy that could enhance the anti-MM activity of Pano while also permitting dose reduction to mitigate unwanted side effects. Specifically, we demonstrate the preclinical potential of combining Pano with the protein disulfide isomerase (PDI) inhibitor, LTI6426 (formerly E64FC26) [16–19]. LTI6426 is an orally bioavailable pan-isof orm inhibitor of PDI that has potent anti-MM activity as a single agent and restores proteasome inhibitor sensitivity in resistant MM cells [16, 17]. PDI possesses two redox active catalytic centers that mediate oxidative protein folding within the endoplasmic reticulum (ER). Specifically, PDI catalyzes the oxidation of cysteine residues in client proteins and introduces and isomerizes inter- and intrachain disulfide bonds to give proteins their proper tertiary and quaternary structures [20, 21]. The dual role of PDI as a regulator of ER and oxidative stress pathways strikes two vulnerabilities of MM plasma cells. Normal and malignant plasma cells are capable of producing thousands of immunoglobulin (Ig) proteins per second [22]. Igs are rich in disulfide linkages and their formation generates equimolar quantities of reactive oxygen species. Similarly, high protein production rates are accompanied by the accumulation of misfolded/unfolded proteins leading to high basal levels of ER stress [23, 24]. Thus, the dual function of PDI makes it an appealing drug target in MM, and we’ve shown that PDI inhibitors are effective when combined with drugs targeting the ubiquitin–proteasome system. In addition to synergy with Btz and other proteasome inhibitors, we found, somewhat unexpectedly, that LTI6426 was also highly synergistic with HDACi but not ~150 other marketed oncology drugs in solid tumor lines [18]. In the current study, we explored the potential of an LTI6426/Pano combination in MM given that it is FDA-approved but underutilized in this indication. We show a synergistic interaction between LTI6426 and Pano as well as other pan and isoform selective HDACi, but not other epigenetic therapies. We went on to characterize the molecular events underlying the anti-MM response to LTI6426/Pano, which induces synergistic transcriptional upregulation of key effectors in the ER stress pathway including ATF3, DDIT3/CHOP, and DNAJB1. We extended our findings to test LTI6426 with Pano in vivo using a mouse model of treatment resistant MM in a multidrug cocktail that also includes Btz, which is representative of the FDA-approved regimen for Pano in relapsed/refractory MM. The three drug cocktail used a low dose of Pano that was well tolerated in vivo and LTI6426 significantly enhanced the Pano regimen to improve animal survival. We validated key transcriptional targets by RT-qPCR (ATF3, DDIT3/CHOP, DNAJB1) that are induced by treatment with Pano and LTI6426 and propose that these biomarkers could serve as potential pharmacodynamic (PD) markers of response to this new therapeutic regimen in clinical development. This work has translational significance as it suggests that the incorporation of LTI6426 into Pano regimens could capture previously unrealized activity of Pano and allow dose reduction to alleviate dose-limiting toxicities for MM patients.

Materials and methods

Cell lines and reagents

Cell lines (KMS11, OPM2, and ANBL6) were purchased from American Type Culture Collection (Manassas, VA, USA). MM.1S BzR cells were a gift from Dr. Brian Van Ness (U. of Minnesota) and have been described previously [25]. LTI6426 was provided by Leukogene Therapeutics, Inc. (Charleston, SC) with purity and identity that was confirmed by liquid chromatograph–mass spectrometry (LC–MS) and nuclear magnetic resonance (NMR) as shown previously [16]. Bortezomib (Catalog No. S1013), carfilzomib (Catalog No. S2853), panobinostat (Catalog No. S1030), vorinostat (Catalog No. S1047), ricolinostat (Catalog No. S8001), entinostat (Catalog No. S1053), romidepsin (Catalog No. S3020), tazemetostat (Catalog No. S7128), ML324 (Catalog No. S7296), JQ1 (Catalog No. S7110), OTX015 (Catalog No. S7360), ABBV744 (Catalog No. S8723), IBET151 (Catalog No. S2780), and GSK-LSD1 (Catalog No. S7574) were purchased from Selleck Chemicals (Houston, TX, USA).

Flow cytometry

Cells were treated as indicated, washed with ice-cold PBS, and collected. The cells were then fixed with the Fixation/Permeabilization Solution Kit from BD Biosciences (San, Jose, CA, USA) according to the manufacturer’s instructions. Cells were then treated with 0.125 mg/mL final concentration of rabbit anti-active caspase-3 (BD Pharmigen; San, Jose, CA, USA) and incubated at room temperature for 20 min. The cells were then washed with 1 mL of permeabilization/wash solution and resuspended in 50 µL of diluted Alexa Fluor 488 goat anti-rabbit IgG (Invitrogen; Carlsbad, CA, USA) according to the manufacturer’s instructions. The cells were then washed with 1 mL of permeabilization/wash solution and resuspended in 300 µL of permeabilization/wash solution and analyzed with the FITC channel of a NovoCyte flow cytometer (Acea Biosciences; San Diego, CA, USA).
**Determination of synergistic drug interactions**

Cell viability was measured using CellTiter-Glo® (Promega; Madison, WI, USA) and a Spectramax L microplate luminometer (Molecular Devices; San Jose, CA, USA). Synergy analysis was conducted as follows using principles of isobologram analysis: cell viability RLU values in the presence and absence of LTI6426 were independently determined and normalized to the zero Pano group to account for any effects of LTI6426 monotherapy. Thus, any separation of the curves indicates a true change in the sensitivity to Pano with a leftward shift in the curve indicating a synergistic drug interaction.

**Biomarker analysis by RT-qPCR**

For quantitative reverse transcriptase polymerase chain reaction (RT-qPCR), total RNA was extracted using the RNeasy Plus Mini Kit (Qiagen; Hilden, Germany) and reversed transcribed and quantified using the Luna Universal One-Step RT-qPCR Kit (New England BioLabs; Ipswich, MA, USA). Primers: Fwd: 5'-GGAGTGCCTGCAAGAAG-3', Rvs: 5'-CCATTGCTGGCATAAAT-3'; DNAJB1 Fwd: 5'-CCAGTCCACCCAGCCTCC-3', Rvs: 5'-CCC TTCCTTCACTTGGATGTCA-3'; DDIT3 Fwd: 5'-GGAGAACAGTGTGATTTCC-3', Rvs: 5'-CTGGTGGCGCCATTTCC-3'; GAPDH Fwd: 5'-ACACTTTTGTATCGTGGAAAG-3', Rvs: 5'-GGCATCACGCACTACG-3'; TPH1 Fwd: 5'-CGAGGTGCGCGCAATCTTC-3', Rvs: 5'-GTTGTCAGCTTCGAGCTA-3'; FTL Fwd: 5'-CACCTGGTCAATTGTACCT-3', Rvs: 5'-GGCCAAATCGGGAAGAAGT-3'; GCLC Fwd: 5'-GGGACAAGGAGCTCTCAAGT-3', Rvs: 5'-CAGACAGGACGACGACGACGAC-3'; GSTP1 Fwd: 5'-CCCTACTCCGTATGCATTTC-3', Rvs: 5'-CCAGGAGGTTGCTAGTGAC-3'; HERPUD1 Fwd: 5'-CGGTCTACACACCTATGTTG-3', Rvs: 5'-TGGAGAGCAGCATGATCTTG-3'; HMOX1 Fwd: 5'-AAGACTTCGGTTCCCTGCA-3', Rvs: 5'-AAAGGCCATCGACACATCGTC-3'; HSPA6 Fwd: 5'-GATGCTGCGTTCCCTGAC-3', Rvs: 5'-CCTCCATGAAATGTGTCACG-3'; NOD-SCID IL2Rγ−/− (NSG) mice (Jackson Laboratory; Bar Harbor, ME, USA) were injected with 100 mg/kg cyclophosphamide i.p. (200 µL total in DPBS). Two days later mice were injected with 1 × 10^6 myeloma cells (MM.1S or MM.1S BzR) (100 µL total in DPBS) in the lateral tail vein. Mice were randomly assigned to treatment groups (N=10) and dosed with drugs as indicated and vehicle contained 0.5% (v/v) DMSO and 5% (v/v) Kolliphor EL (200 µL total in DPBS). Treatments were initiated on day 14 post injection of MM cells. Treatments were as follows: (1) vehicle, (2) oral LTI6426 (10 mg/kg/day, continuous) (3) the combination of Btz (0.4 mg/kg, days 1, 3, 5, and 8, i.p.) and Pano (4 mg/kg, days 1, 3, 5, 8, 10, and 12, i.p.), and (4) a triple treatment of LTI6426, Btz, and Pano in 21-day cycles. For experiments quantifying the number of MM plasma cells in the bone marrow of mice, hind leg femurs were harvested, stripped of soft tissue, and marrow exposed by a sagittal cut with a sharp blade. Bone marrow cells were collected in cold PBS, stained with a PE-conjugated anti-CD138 antibody (Miltenyi Biotec; Bergisch Gladbach, Germany), and quantified by flow cytometry. For statistical power calculations, a sample size of 10 mice per group yielded 81% power to detect significant differences in survival rate (10% vs. 75%) between control and treatment groups at 8 weeks with Type I error α of 0.0167 (= 0.05/3) based on the log-rank test. The assumption of 10% survival in the control group and 75% in the treatment group(s) was made based on our experience with this model. The Kaplan–Meier curve and a log-rank (Mantel–Cox) test were used to analyze survival related outcomes.

**Results**

**The indene PDI inhibitor, LTI6426, potentiates the anti-MM activity of Pano and other HDACi**

Animal experiments were conducted as described previously [17] under the approval of the Institutional Animal Care and Use Committee (IACUC) of the Medical University of South Carolina (MUSC, Protocol #2020-00915). NOD-SCID IL2Rγ−/− (NSG) mice (Jackson Laboratory; Bar Harbor, ME, USA) were injected with 100 mg/kg cyclophosphamide i.p. (200 µL total in DPBS). Two days later mice were injected with 1 × 10^6 myeloma cells (MM.1S or MM.1S BzR) (100 µL total in DPBS) in the lateral tail vein. Mice were randomly assigned to treatment groups (N=10) and dosed with drugs as indicated and vehicle contained 0.5% (v/v) DMSO and 5% (v/v) Kolliphor EL (200 µL total in DPBS). Treatments were initiated on day 14 post injection of MM cells. Treatments were as follows: (1) vehicle, (2) oral LTI6426 (10 mg/kg/day, continuous) (3) the combination of Btz (0.4 mg/kg, days 1, 3, 5, and 8, i.p.) and Pano (4 mg/kg, days 1, 3, 5, 8, 10, and 12, i.p.), and (4) a triple treatment of LTI6426, Btz, and Pano in 21-day cycles. For experiments quantifying the number of MM plasma cells in the bone marrow of mice, hind leg femurs were harvested, stripped of soft tissue, and marrow exposed by a sagittal cut with a sharp blade. Bone marrow cells were collected in cold PBS, stained with a PE-conjugated anti-CD138 antibody (Miltenyi Biotec; Bergisch Gladbach, Germany), and quantified by flow cytometry. For statistical power calculations, a sample size of 10 mice per group yielded 81% power to detect significant differences in survival rate (10% vs. 75%) between control and treatment groups at 8 weeks with Type I error α of 0.0167(= 0.05/3) based on the log-rank test. The assumption of 10% survival in the control group and 75% in the treatment group(s) was made based on our experience with this model. The Kaplan–Meier curve and a log-rank (Mantel–Cox) test were used to analyze survival related outcomes.

We previously reported the discovery, medicinal chemistry optimization, and the potency and selectivity of an alkanyl indene class of PDI inhibitor (LTI6426; previously E64FC26) in biochemical assays and MM and solid tumor models [16–18]. To explore the potential of an LTI6426 and Pano combination in MM, we screened a panel of MM cell lines for synergistic cytotoxic activity. Cell models included KMS-11 and OPM2, which represent the high risk t(4;14) cytogenetic subclass [26, 27], proteasome inhibitor resistant MM.1S BzR cells, and ANBL6 cells, which others have
shown are a close genomic representation of primary patient MM [28]. We observed true synergy between LTI6426 and Pano in all four cell lines, as indicated by the leftward shift of the Pano cell viability dose curve in the presence of LTI6426. The Effective Concentration 50 (EC50) values for Pano decreased in the presence of LTI6426 from 11.3 to 1.5 nM (a 7.5-fold increase in sensitivity), 16.6–0.6 nM (26-fold), 12.0–0.9 nM (6.3-fold), and 20.9–0.7 nM (30-fold) in KMS-11, OPM2, MM.1S BzR, and ANBL6 cells, respectively (Fig. 1A, B). Isobologram analysis was conducted and confirmed the synergistic nature of the drug interaction as indicated by the leftward shift of the LTI6426/Pano curve relative to the no effect/additive isobole (Fig. 1C). The synergy was largely due to apoptotic cell death as the combination synergistically increased caspase-3 cleavage/activation (Fig. 2A). In KMS11 cells, cleaved caspase-3 (CC3) levels increased by 73% in the combination group compared to the predicted additive effect of 27% that would have resulted if LTI6426 (20%) and Pano (7%) monotherapies were interacting in a purely additive fashion. Likewise, in OPM2 cells, the individual LTI6426 (17%) and Pano (17%) monotherapies would have generated a predicted 34% increase in CC3 if the effect were additive, but the actual increase was 66%, indicating a synergistic effect. This synergy was absent in normal human peripheral blood mononuclear cells (PBMCs), where LTI6426 had an antagonistic effect on Pano, reducing sensitivity by 1.7-fold (9.6 nM–17 nM, p = 0.0111, Fig. 2B, C). Taken together, PDI inhibition with LTI6426 enhances Pano-induced MM cell death and apoptosis in a heterogenous group of MM cell models. This combination is truly synergistic in MM cells but not normal PBMCs, suggesting this is not a generalized effect but one that is dependent on the biology of MM cells.

We next tested whether the synergy between LTI6426 and Pano was observed with other epigenetic drugs in MM models. Indeed, a synergistic drug interaction was evident with other HDACi, including the pan-HDACi, vorinostat, and the isoform selective HDACi, ricolinostat (HDAC6) [29], romidepsin (class I HDACs) [30], and entinostat (class I HDACs) [31] (Fig. 3A, B). MM.1S BzR was the exception, showing synergy between LTI6426 and only the pan-HDACi, Pano and vorinostat. Negligible synergy (< twofold) was observed for combinations of LTI6426 and other classes of epigenetic modifying drugs (Fig. 3A and C). The drugs we tested included inhibitors of lysine specific demethylase 1 (LSD1, GSK-LSD1), EZH2 (taznetostat), Jumonji domain
containing demethylase 2 (JMJD2, ML324), the demethylating agent, 5-Azacitidine, and BET/bromodomain inhibitors (ABBV-744, OTX015, IBET151, and JQ1). These results indicate that LTI6426 enhances the anti-MM activity of HDACi, but not all epigenetic drugs. This further suggests that molecular events downstream of PDI and HDAC inhibition converge in a specific manner to drive MM cell death.

ATF3, DDIT3/CHOP, and DNAJB1 induction characterize the molecular response to LTI6426/Pano combinations

We next set out to explore and characterize the molecular underpinnings of the synergy between LTI6426 and Pano in MM cells. Our previous work demonstrated a convergence of HDACi on the unfolded protein response (UPR)/ER stress and oxidative stress transcriptional programs that are activated in response to PDI inhibition [16–18]. To evaluate the effects of the combination on these two stress pathways, we constructed an array of gene targets from UPR/ER stress (ATF3, DDIT3, HERPUD1, HSPA6, and DNAJB1) and oxidative stress pathways (FTH, FLT, HMOX1, NQO1, GCLC, GSTP1, NFE2L2, TXN, and TXNRD1). We then measured the expression of these gene targets by RT-qPCR after treatment with LTI6426, Pano, or the combination. Single agent LTI6426 induced an ER stress and oxidative stress signature predominantly characterized by up-regulation of ATF3, DDIT3/CHOP, HSPA6, DNAJB1, and HMOX1 in all three cell lines that were evaluated (Fig. 4A). Single agent Pano induced minimal effects on this gene set with ATF3 being the only gene that was significantly induced by greater than fourfold in all three cell lines. Most importantly, the combination of LTI6426/Pano drove a synergistic induction of a small subset of these genes. Specifically, ATF3, DNAJB1 and DDIT3 (CHOP) gene induction was potentiated by the combination to a degree that far exceeded the sum of each individual treatment (Fig. 4A, B). For example, ATF3 was induced by 89.6-fold in the LTI6426/Pano group compared to a predicted additive effect of 11.4-fold in KMS11 (p = 0.0004), 69-fold compared to 15.7-fold in OPM2 (p < 0.001), and 53-fold compared to a predicted 27.7-fold in MM.1S BzR cells (p < 0.001; Fig. 4B). Transcriptional effects were mirrored at the protein level, as the combination significantly increased ATF3 protein levels compared to the individual treatments (Fig. 4C). CHOP was also potentiated by the LTI6426/Pano combination at the protein level, although to a lesser extent than ATF3, whereas DNAJB1 protein was only modestly induced and there was no difference between LTI6426 monotherapy and the combination in OPM2 cells. As we have shown previously, LTI6426 induces a trademark smear of poly-ubiquitinated proteins due to protein folding errors caused by inhibition of PDI. Thus, the
molecular effects of the LTI6426/Pano combination intersects at the transcriptional level to induce a unique gene expression signature characterized predominantly by ATF3, DDIT3, and DNAJB1 induction. This suggests that these targets, particularly ATF3, may be key effectors in the synergistic anti-MM apoptotic response to the combination, and further identifies ATF3, DDIT3/CHOP, and DNAJB1 mRNA are biomarkers of response to this new drug combination.

**LTI6426 enhances the anti-MM effects of Pano-based drug regimens in vivo**

We next evaluated the potential of LTI6426/Pano combination in a human xenotransplant preclinical model of MM. This model incorporates intravenous injection of proteasome inhibitor resistant MM.1S BzR cells and faithfully models the human pathology of relapsed/refractory MM with colonization of the bone marrow by CD138+ MM plasma cells and poor sensitivity to Btz therapy [17]. As Pano is indicated for relapsed/refractory MM in a regimen with Btz, we randomized mice into groups that would receive (1) vehicle, (2) oral LTI6426 (10 mg/kg/day, continuous) (3) the combination of Btz (0.4 mg/kg, days 1, 3, 5, and 8, i.p.) and Pano (4 mg/kg, days 1, 3, 5, 8, 10, and 12, i.p.), and (4) a triple treatment of LTI6426, Btz, and Pano in 21-day cycles. In vitro experiments were first conducted and showed a synergistic effect of LTI6426 on Btz and Pano, both independently and as a triple treatment (Fig. 5A). Similar experiments showed a comparable three-way synergy between LTI6426, Pano, and the second generation proteasome inhibitor, carfilzomib (Crflz, Fig. 5A). In vivo, the triple treatment of LTI6426, Btz, and Pano was highly efficacious, increasing median survival from 50 days (vehicle control group) to 74 days (p < 0.0001; N = 10; Fig. 5B). The individual treatment arms also increased median survival. The Btz/Pano treatment cohort showed an improvement in survival of 9 days compared to vehicle (p = 0.0049, N = 10) and the LTI6426 monotherapy improved median survival by 10 days (p = 0.006, N = 10). However, survival in the individual treatment cohorts was inferior when compared to the triple treatment of LTI6426/Btz/Pano (p = 0.0124 for Btz/Pano vs. LTI6426/Btz/Pano and p = 0.0302 for LTI6426 vs. LTI6426/Btz/Pano). All treatments were well tolerated as body weight remained constant throughout the experiment (Fig. 5C), and animals did not exhibit any overt visual or behavioral signs of distress. Notably, we observed a strong effect of the combination even though Pano was given at a dose of 4 mg/kg on days 1, 3, 5, 8, 10, and 12 of a 21-day cycle.
cycle. The dose and dosing schedule we chose was lower and less frequently administered than what was used in published studies of Pano. Doses in these previous studies ranged from 5–25 mg/kg given on a continuous daily schedule [32–34]. Given that DNAJB1, ATF3, and DDIT3 were biomarkers of the LTI6426/Pano combination response in cell models, we next asked whether those markers were induced in vivo. Bone marrow was harvested from femurs of mice from vehicle and LTI6426 + Btz/Pano treatment groups as they reached the survival endpoint. Animals were dosed with the final vehicle or triple treatment 48 h prior to the survival endpoint. RNA was extracted from an equal number of MM plasma cells in vehicle and treatment groups (Fig. 5D, left panel) and human DNAJB1, ATF3, and DDIT3 transcript levels were measured by RT-qPCR. Similar to what we observed in cell culture models, DNAJB1 and ATF3 expression were significantly higher in the LTI6426 + Btz/Pano group (p = 0.0237 and 0.0498, respectively, N = 9; Fig. 5D, right panels). DDIT3/CHOP levels showed an increasing trend, although the difference between the groups did not reach statistical significance. We conclude that LTI6426 enhances the activity of a clinically relevant Pano regimen in vivo, and this only required low Pano doses that were well tolerated in mice with the inclusion of other MM standard of care agents (i.e., Btz). The key transcriptional networks that were activated in response to this synergistic combination using cell model systems were found to be up-regulated in MM plasma cells from the bone marrow of mice treated with LTI6426 + Btz/Pano mice. These molecular findings provide a mechanistic understanding of the drug synergy and offer candidate biomarkers for assessing response and pharmacodynamics.

Discussion

Epigenetic dysregulation is a hallmark of malignant cells. In response to this observation, therapeutic platforms (e.g., HDACi, BET/Bromodomain inhibitors, etc.) were developed to normalize the epigenome for clinical gain. Multiple HDACi (Pano, vorinostat, romidepsin, belinostat) have been approved for the treatment of cancer, although their impact has been limited to cutaneous and peripheral T-cell lymphoma (CTCL and PTCL) and MM [5, 35–37], which account for less than 1% of all cancers [38]. In MM, Pano is used sparingly in the clinic despite FDA approval and its
high potency and specificity for HDACs. For example, a study in MM patients from Japan showed that only a small fraction of eligible patients were prescribed Pano compared to other novel agents [39]. A comparable study based on electronic health records between 2011 and 2019 showed a similar trend in the US [40]. This is due in part to the high grade AEs that are observed with the FDA-approved Pano/Btz/dexamethasone regimen [41]. However, it may also reflect the increasingly complex nature of the MM therapeutic paradigm and the fact that Pano is reserved for heavily pretreated late stage patients who have received, on average, four previous lines of therapy and are commonly refractory to a proteasome inhibitor and immunomodulatory agent (IMiD) [42]. In addition, the recent entry of several new therapeutic agents into the MM space further complicates if/how Pano might best be incorporated into regimens of those new agents. Recent studies have integrated Pano into regimens that eliminated dexamethasone (i.e., steroid-sparing) and switch to the proteasome inhibitor carfilzomib [13, 14], which has a different toxicity profile than Btz. Early evidence suggests that this approach is efficacious and tolerable, perhaps allowing for increased flexibility in the Pano dosing and schedule. Our data show a strong synergy between LT6426 and Pano at low doses of Pano, suggesting that this combination would permit Pano dose reduction and alleviate toxicity while maintaining the anti-MM activity. We used a low dose of Pano (4 mg/kg, i.p.) for 6 days of a 21-day cycle. It is difficult to accurately translate dose level between mice and humans; however, pharmacokinetic (PK) data from preclinical and clinical Pano studies suggest that drug exposure...
levels from our dosing regimen would have been far lower than what is achieved in humans. For example, a single i.p. dose of 10 mg/kg Pano, which is 2.5 times the dose we used, produced maximum blood plasma concentrations ($C_{\text{max}}$) of approximately 860 pM (300 pg/ml) in C57BL/6 mice [43]. By comparison, plasma drug concentrations in humans were significantly higher in clinical PK studies, as a single oral dose of Pano at 20 mg generated $C_{\text{max}}$ levels close to 60 nM (2100 pg/ml) [44, 45], or approximately 70-fold higher exposure in humans than mice. We can therefore conclude by inference that the combination of LTI6426, Btz, and Pano demonstrated a significant increase in animal survival using a Pano dose that produced systemic drug concentrations much lower than what is achievable in patients. Our analysis of LTI6426 metabolism revealed no overlap with Pano regarding hepatic cytochrome P450 (CYP) enzyme affinity, thereby ruling out drug-drug interactions as the source of synergy with Pano in vivo. CYP3A4 and to a lesser extent, CYP2D6, are the primary enzymes responsible for hepatic Pano metabolism [46]. LTI6426, by comparison, showed negligible affinity for both CYP3A4 and CYP2D6 in inhibition studies using liver microsomes. LTI6426 was a weak CYP3A4 inhibitor in inhibition studies using liver microsomes. LTI6426 was a weak CYP3A4 inhibitor in vitro with an inhibitory concentration 50 (IC$_{50}$) of > 100 μM (midazolam) and 18.2 μM (testosterone) and was a weak inhibitor of CYP2D6 with an IC$_{50}$ of 10.5 μM (dextromethorphan). In depth safety and pharmacokinetic/pharmacodynamic studies evaluating LTI6426 + Pano combinations are required in large animals and ultimately humans to conclusively determine drug dosing and systemic exposure levels.

PDI regulates protein folding and redox homeostasis, two vulnerabilities of MM that are dictated by the biology of the plasma cell as a mass producer of Ig proteins [47, 48]. Indeed, we and others have shown that MM cells are highly sensitive to PDI inhibitors as single agents [17, 49]. The structure of IgG molecules includes 12 disulfide bonds and it has been shown that PDI associates with Ig molecules and is critical for their proper folding [50, 51]. As such, PDI inhibition leads to a dramatic spike in misfolded poly-ubiquitinated proteins and ER stress and oxidative stress biomarkers [16–18]. We set out to identify biomarkers of the LTI6426/Pano combination in MM cells, focusing on the ER and oxidative stress pathways. From a panel of ER and oxidative stress transcriptional targets we found that $ATF3$, $DDIT3$ (CHOP), and $DNAJB1$ were synergistically up-regulated in response to the combination. From this observation, we postulate that Pano alters chromatin topography by altering histone acetylation in way that promotes the transcription of $ATF3$, $DDIT3$, and $DNAJB1$, which are induced by PDI inhibition and subsequent ER stress pathway activation. In a previous study we conducted comprehensive molecular analysis that confirmed this mechanism in solid tumor types [18], and our current study demonstrates that this mechanism is broadly active across hematological as well as solid tumor types. The current study builds on the earlier work by confirming the induction of these markers by RT-qPCR in MM bone marrow aspirates from mice in our in vivo studies, suggesting that these gene targets may be useful pharmacodynamic (PD) markers in clinical applications. PD markers are increasingly being incorporated into early stage clinical trial design to confirm target engagement and proof-of-mechanism in patients, to optimize dosing, and to guide “go, no-go” development decisions [52, 53]. Therefore, $ATF3$, $DDIT3$/CHOP, and $DNAJB1$ are candidate PD markers for future MM trials that layer LTI6426 onto Pano-based regimens. In conclusion, this study demonstrates the potential of PDI inhibitors like LTI6426 to enhance the anti-MM activity of Pano. The potentiating effects of LTI6426 on HDACi in MM cells may enhance Pano efficacy and allow for dose reductions that mitigate toxicities in heavily treated relapsed/refractory MM patient populations.

**Funding** American Cancer Society (RSG-14-156-01-CDD) to N.G.D., the NIH/NCI (R42CA213488) to N.G.D., the NIH/NCI (R01CA245081) to N.G.D., and by the Hollings Cancer Center T32 Ruth L. Kirschstein National Research Service Award Training Program T32 (CA193201). Supported in part by the Biostatistics Shared Resource, Hollings Cancer Center, Medical University of South Carolina (P30 CA138313).

**Data availability statement** All data generated or analyzed during this study are included in this published article.

**Declarations**

**Conflict of interest** N.G.D. owns equity in Leukogene Therapeutics, Inc. N.G.D. and R.M.R. are inventors on patents.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Walker BA et al (2011) aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 117(2):553–562
2. Dimopoulos K, Gimsing P, Gronbaek K (2014) The role of epigenetics in the biology of multiple myeloma. Blood Cancer J 4:e207
3. Feinberg AP, Vogelstein B (1983) Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301(5895):89–92
4. Fraga MF et al (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37(4):391–400
5. San-Miguel JF et al (2014) Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 15(11):1195–1206
6. Richardson PG et al (2018) Patient-reported outcomes of multiple myeloma patients treated with panobinostat after >2 lines of therapy based on the international phase 3, randomised, double-blind, placebo-controlled PANORAMA-1 trial. Br J Haematol 181(5):628–636
7. San-Miguel JF et al (2016) Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematol 3(11):e506–e515
8. Atadja P (2009) Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 280(2):233–241
9. Liu JD et al (2016) Efficacy and safety of panobinostat in relapsed or refractory multiple myeloma: meta analyses of clinical trials and systematic review. Sci Rep 6:27361
10. Richardson PG et al (2013) PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 122(14):2331–2337
11. DeAngelo DJ et al (2013) Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia 27(8):1628–1636
12. Wolf JL et al (2012) Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma 53(9):1820–1823
13. Kaufman JL et al (2019) Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. Blood Cancer J 9(1):3
14. Berdeja JG et al (2015) Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. Haematologica 100(5):670–676
15. Yee AJ, Raje NS (2018) Panobinostat and multiple myeloma in 2018. Oncologist 23(5):516–517
16. Robinson RM et al (2020) Tuning isoform selectivity and bortezomib sensitivity with a new class of alkylindene PDI inhibitor. Eur J Med Chem 186:111906
17. Robinson RM et al (2019) Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma. Leukemia 33(4):1011–1022
18. Duncan RM et al (2020) ATF3 coordinates antitumor synergy between epigenetic drugs and protein disulfide isomerase inhibitors. Cancer Res 80(16):3279–3291
19. Hurst KE et al (2019) Endoplasmic reticulum protein disulfide isomerase shapes t cell efficacy for adoptive cellular therapy of tumors. Cells 8(12):1514
20. Wang L, Wang X, Wang CC (2015) Protein disulfide-isomerase, a folding catalyst and a redox-regulated chaperone. Free Radic Biol Med 83:305–313
21. Feige MJ, Hendershot LM (2011) Disulfide bonds in ER protein folding and homeostasis. Curr Opin Cell Biol 23(2):167–175
22. Shimizu Y, Hendershot LM (2009) Oxidative folding: cellular strategies for dealing with the resultant equimolar production of reactive oxygen species. Antioxid Redox Signal 11(9):2317–2331
23. Brewer JW, Hendershot LM (2005) Building an antibody factory: a job for the unfolded protein response. Nat Immunol 6(1):23–29
24. Cenci S, Sitiia R (2007) Managing and exploiting stress in the antibody factory. FEBS Lett 581(19):3652–3657
25. Thompson RM et al (2017) Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells. Onco-target 8(22):35863–35876
26. Bergsagel PL et al (2013) Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 121(6):884–892
27. Chesi M et al (1997) Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16(3):260–264
28. Sarin V et al (2020) Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis. Leukemia 34(10):2754–2765
29. Santo L et al (2012) Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 119(11):2579–2589
30. Furumai R et al (2002) FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62(17):4916–4921
31. Suzuki T et al (1999) Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 42(15):3001–3003
32. Floris G et al (2009) High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model. Clin Cancer Res 15(12):4066–4076
33. Ocio EM et al (2010) In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica 95(5):794–803
34. Matthews GM et al (2013) Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5–1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma. Cell Death Dis 4:e4798
35. Mann BS et al (2007) Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 13(8):2318–2322
36. Lee HZ et al (2015) FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clin Cancer Res 21(12):2666–2670
37. Piekarz RL et al (2011) Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117(22):5827–5834
38. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7–34
39. Uno S et al (2020) Current treatment patterns and medical costs of multiple myeloma in Japan: a cross-sectional analysis of a large population of multiple-myeloma patients. Br J Haematol 181(5):628–636
40. Braunlin M et al (2020) Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011–2019 oncology claims data. J Oncol Pharm Pract. https://doi.org/10.1080/10428194.2020.1827253
41. Bird S et al (2020) A real-world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated world settings versus randomized controlled trials. J Oncol Pharm Pract. https://doi.org/10.1080/10428194.2020.1827253
42. Borrelli EP, McGladrigan CG (2020) Differences in safety profiles of newly approved medications for multiple myeloma in real-world settings versus randomized controlled trials. J Oncol Pharm Pract. https://doi.org/10.1080/10428194.2020.1872753
43. Bird S et al (2020) A real-world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple-myeloma patients. Br J Haematol 191(5):927–930

Springer
43. Chopra V et al (2016) LBH589, a hydroxamic acid-derived hdac inhibitor, is neuroprotective in mouse models of huntington’s disease. J Huntingt Dis 5(4):347–355
44. Mu S et al (2016) Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma. Eur J Clin Pharmacol 72(2):153–161
45. Van Veggel M, Westerman E, Hamberg P (2018) Clinical pharmacokinetics and pharmacodynamics of panobinostat. Clin Pharmacokinet 57(1):21–29
46. Einolf HJ et al (2017) Physiologically based pharmacokinetic model predictions of panobinostat (LBH589) as a victim and perpetrator of drug-drug interactions. Drug Metab Dispos 45(12):1304–1316
47. Meister S et al (2007) Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 67(4):1783–1792
48. Lipchick BC, Fink EE, Nikiforov MA (2016) Oxidative stress and proteasome inhibitors in multiple myeloma. Pharmacol Res 105:210–215
49. Vatolin S et al (2016) Novel protein disulfide isomerase inhibitor with anticancer activity in multiple myeloma. Cancer Res 76(11):3340–3350
50. Roth RA, Pierce SB (1987) In vivo cross-linking of protein disulfide isomerase to immunoglobulins. Biochemistry 26(14):4179–4182
51. Liu H, May K (2012) Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function. MAbs 4(1):17–23
52. Tan DS et al (2009) Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J 15(5):406–420
53. Parchment RE, Doroshow JH (2016) Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development. Semin Oncol 43(4):514–525

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.